Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-vers…
What to know about INCY
Incyte Corporation is a large Healthcare company with a mixed financial profile. It scores well on growth and health, but size is worth keeping an eye on.
Should you consider INCY?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
Incyte Corporation is a large-cap Healthcare company with a mixed overall financial profile — it ranks in the top quarter of its Healthcare peers (14 of 59).
-
The business is both profitable and financially healthy — it keeps a good portion of what it earns and carries its debt comfortably.
-
Valuation looks attractive — the stock is priced reasonably relative to its earnings and sales compared to most peers. You're not overpaying for the business.
-
Growth is a clear strength — revenue and earnings are expanding faster than most peers, signalling strong demand for the company's products or services.
-
This stock pays no dividend — your return depends entirely on the share price rising over time.
-
Volatility is close to the S&P 500 average — typical market swings, nothing unusual.
-
Analyst sentiment is cautious and short interest is relatively elevated — meaning some professional investors are actively betting the price will fall. Worth understanding why.
-
This is a mixed picture — real strengths in some areas, but areas that need watching too. Do your homework on the sector before deciding.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how INCY compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 13.87 | Top 25% |
| Forward P/E | 10.72 | Top 25% |
| PEG Ratio | 0.36 | Top 25% |
| Price to Sales | 3.66 | Average |
| Price to Book | 3.49 | Average |
| EV/EBITDA | 10.30 | Top 25% |
| Earnings Yield | 7.21% | Top 25% |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 52.77% | Above avg |
| Operating Margin | 25.55% | Above avg |
| Net Profit Margin | 26.71% | Top 25% |
| Return on Equity | 30.82% | Top 25% |
| Return on Invested Capital | 13.89% | Top 25% |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 20.90% | Top 25% |
| Revenue Growth (3Y CAGR) | 14.84% | Top 25% |
| EPS Growth (YoY) | 83.80% | Top 25% |
| Free Cash Flow Growth | 465.38% | Top 25% |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 3.68 | Top 25% |
| Debt to Equity | 0.70 | Above avg |
| Interest Coverage | 686.52 | Top 25% |
| Altman Z-Score | 8.75 | Top 25% |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | — | N/A |
| Payout Ratio | 0.00% | Top 25% |
| Dividend Growth (5Y) | — | N/A |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 7.24% | Top 25% |
| OCF to Sales | 28.29% | Above avg |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 0.79 | Above avg |
| Volatility (30-Day) | 35.75% | Average |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 9.83% | Below avg |
| Avg. Analyst Rating | 2.41 | Below avg |
| Target Upside % | 11.06% | Average |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 19.62B | Below avg |
How does INCY compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to INCY — based on their financial profile.